Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients (a Phase I Study)

Trial Profile

Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients (a Phase I Study)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs Natural killer cell therapy (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions
  • Acronyms INTRO
  • Most Recent Events

    • 01 Nov 2018 Last checked against ClinicalTrials.gov record.
    • 30 Aug 2018 Planned initiation date changed from 1 May 2018 to 1 Nov 2018.
    • 01 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top